Hospitals May Be Overcharging for Hip, Knee Replacements

Share this content:
Hospitals May Be Overcharging for Hip, Knee Replacements
Hospitals May Be Overcharging for Hip, Knee Replacements

WEDNESDAY, March 1, 2017 (HealthDay News) -- Some U.S. hospitals might be charging private insurers twice as much for knee and hip replacements as the implants typically cost, according to a research letter published in the Feb. 28 issue of the Journal of the American Medical Association.

Yi-Ju Tseng, Ph.D., and Kenneth Mandl, M.D., M.P.H., of the Computational Health Informatics Program at Boston Children's Hospital, looked at statistics from a single private insurance plan from 2011 to 2015. They focused on 40,372 patients with knee replacements and 23,570 patients with hip replacements. They compared the costs paid by the insurers for the implants to the average costs of the implants, as disclosed by a group of 160 hospitals and another group of 1,500 hospitals.

The researchers found that the insurer paid an average of $10,604.52 for knee implants and $11,751.25 for hip implants, along with related supplies. But the average cost of the implants and related supplies, as determined by the group of 160 hospitals, was $5,023.01 for knee and $5,619.75 for hip. The average prices for the other hospital group were similar.

The numbers suggest that insurers paid an average of $5,600 more for knee implants and $6,100 more for hip implants than the average prices, the study authors said. The authors noted that their research had limitations. It only looked at one insurer, and all the patients were under 65.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »